Coronavirus vaccine: Vaccine will be efficient against Omicron strain, Sputnik said.
Moscow:
The Russian Ministry of Health has registered the nasal version of Sputnik V, the world’s first nasal vaccine against COVID-19.
“The Russian Ministry of Health is registering the nasal version of Sputnik V, the world’s first nasal vaccine against COVID-19,” Sputnik V tweeted late Friday.
In January, the Russian news agency TASS reported that the nasal vaccine against the new coronavirus infection will be in civilian circulation and available to Russians within three to four months, said Gamaleya Center director Alexander Gintsburg.
“The nasal vaccine for civilian circulation will be available in three to four months,” the director had said.
It will be efficient against the new Omicron coronavirus strain, Gintsburg said.
“Laboratory tests show that the Sputnik V protects against the Omicron in its regular injection form, and it will certainly be efficient in the nasal form,” he added, according to TASS.
In October last year, the Russian Ministry of Health licensed the Gamaleya Center for the second phase of clinical trials of the coronavirus vaccine in nasal spray form.
The Sputnik V COVID-19 vaccine was first administered in India in Hyderabad in May 2021. The first shipment of 1.50 lakh doses of Sputnik-V vaccine landed in India on May 1. The Sputnik-V vaccines were supplied to India by Russian Direct. Investment Fund (RDIF) in collaboration with Dr. Reddy’s Laboratories.
“The Sputnik-V vaccine, which has arrived in Hyderabad from Russia, will contribute to the country’s vaccine arsenal to end the pandemic. This third option (along with Covaxin and Covishield) will increase our vaccine capacity and accelerate our vaccination campaign,” official spokesman, the Ministry of Foreign Affairs, Arindam Bagchi had said.
The Sputnik-V vaccine was developed by researchers at the Gamaleya National Research Center for Epidemiology and Microbiology in Moscow.
